Tony Huge

Does TRT Cause Hair Loss? Gel vs Injections vs Enclomiphene: Tony Huge’s Video Guide

Table of Contents

Tony Huge has run testosterone for 14 years and still has his hair, and this video is his attempt to explain why that might not be luck. His answer to the TRT hair loss question is that male pattern baldness is a DHT problem rather than a testosterone problem, which means the route you use to raise testosterone matters more than the number you land on. He compares gel, injections, and enclomiphene on one metric, how much DHT each one generates per unit of testosterone, and then tells you exactly where the hormone data ends and the guesswork begins.

Video: Does TRT Cause Hair Loss? Gel vs Injections vs Enclomiphene. Published August 13, 2026. Watch on YouTube.

What the video covers

The enzyme, not the hormone

Everything in the video rests on one piece of biology. Male pattern baldness is not driven by testosterone. It is driven by dihydrotestosterone binding to androgen receptors in scalp follicles that are genetically sensitive to it. That binding shortens the growth phase and shrinks the follicle a little more each cycle until it stops producing visible hair. The enzyme in the middle is 5-alpha reductase, which converts testosterone into DHT.

Tony’s point is that any intervention that raises testosterone gives that enzyme more to work with, so nothing here is neutral. All three routes produce more DHT. The question is not whether you make more, it is how much and in what proportion, and that turns out to depend almost entirely on how the testosterone got into your body.

Why gel loses and injections only half win

The case against gel is anatomical. Skin is dense with 5-alpha reductase type 2. When you rub testosterone onto your shoulders or thighs, a large share of it meets that enzyme in the skin and converts to DHT locally before it reaches your bloodstream. Your own regulation never gets a say, because the conversion happened where you put the drug.

Tony cites a three-month trial in which topical testosterone took DHT from about 15 ng/dL up to 51.6. The two enclomiphene groups in the same trial landed at 20.4 and 23.2, which he summarizes as roughly 2.5 times the DHT at similar total testosterone. He also cites pooled data putting the DHT rise from transdermal testosterone at roughly 5.5 times baseline against roughly 2.2 times for intramuscular, for comparable testosterone gains.

Injections beat gel because the drug goes into muscle and skips the dermal enzyme layer on the way in. But Tony is careful not to call them clean. An injection is exogenous testosterone. Your body did not make it, cannot regulate it, and responds by shutting down the signal from the brain to the testicles. On the hair question specifically, injections are a real improvement over gel; on the wider question of what happens to your own axis, they carry a separate cost.

Upstream instead of downstream

Enclomiphene is the route Tony expects to win, and the reason is where it acts. It contains no testosterone. It blocks estrogen at the hypothalamus and pituitary, so the brain stops receiving the signal that says you have enough, sends more LH and FSH to the testicles, and the testicles make more testosterone. That testosterone enters circulation the way testosterone always has, meets your normal enzyme density in your normal tissues, and converts at your normal rate. The DHT rise is proportional because you turned up a regulated system rather than pouring substrate in from outside.

“The figure that matters for hair is not how much DHT you have, it’s the ratio of DHT to testosterone.”

Tony Huge, 04:29

That ratio is the number he wants viewers to watch. DHT rising alongside testosterone means the whole androgen system moved up together. DHT rising against testosterone means the conversion itself shifted and follicles are seeing a bigger share of DHT than before. In a 48-week randomized trial he cites, the fixed 25 mg enclomiphene group raised DHT by 20.75 ng/dL, statistically significant against placebo, while the DHT-to-testosterone ratio in the same group moved by zero.

Tony then argues against himself. A hair follicle does not see a ratio, it sees a concentration. If the scalp responds to absolute DHT rather than the balance, then a 20.75-point rise is a 20.75-point rise and the fact that testosterone climbed with it does not help. Nobody has settled that question and the study never tested it on the scalp. His answer is that enclomiphene produces both the smallest absolute rise and the flattest ratio of the three routes, so it wins on either reading, but the ratio argument remains a framework until somebody counts hairs.

The pooled data and the estrogen tilt

To show this is not one trial’s quirk, Tony cites a 2025 meta-analysis of the randomized data, run by researchers with no stake in the molecule. The drug class raised DHT by 7.58 ng/dL against placebo, with a confidence interval of 3.42 to 11.73. The detail he wants you to notice is heterogeneity, the measure of how much trials disagree with each other. On most endpoints in this literature it runs high, sometimes near 90%. On DHT it was 5%, the lowest of any endpoint in the analysis. The trials agree: a modest, consistent, proportional DHT rise.

The secondary argument runs in the same direction. Estrogen is protective for hair; it lengthens the growth phase and partly counteracts DHT-driven miniaturization. Enclomiphene has no meaningful estrogenic activity in peripheral tissue, so it does nothing for the scalp directly, but because your own testosterone is higher there is more substrate for aromatase and estradiol rises modestly with it. Tony calls this a mild systemic tilt in the favorable direction and says it will not override strong genetic sensitivity in a man already losing hair.

Cheat Sheet Pivot

What Tony reported in the video and what the cited trials administered, not instructions for anyone else.

  • Tony ranks the three routes on DHT exposure: gel worst, injections in the middle, enclomiphene best. He is explicit that this ranking is mechanistic and comes from comparative hormone measurements in men, not from hair counts.
  • The trials he cites used a fixed 25 mg enclomiphene dose over 48 weeks and a three-month topical testosterone comparison; every figure in the video is what a named trial administered.
  • Tony’s own approach after 14 years on testosterone is to run TRT and enclomiphene at the same time, to keep some of his natural production going, and to take Enhanced Labs Organ Support, which contains saw palmetto and which he says lowers his DHT a little.
  • He says outright that if hair is the top priority, the least risky option for follicles is not raising testosterone at all. The video is for the man who has already decided he wants high testosterone.
  • Enclomiphene is not FDA approved, though Tony expects it will be.

The compound references Tony keeps coming back to are collected in the Miracle Molecules Cheat Sheet. For how Tony has run enclomiphene as a standalone option, read Enclomiphene: The TRT Alternative That Keeps You Fertile, and for what he does on the follicle side of the equation, see The Full Hair Loss Reversal Stack.

Where the evidence stops

Tony calls this the honest limit, and it is a real one. Nobody has counted hairs in any of these studies. Across eight registered enclomiphene trials, zero hair loss events were reported in any arm, which sounds reassuring until you look at how the tables were built. Those trials used 3% and 5% reporting thresholds, so a genuine 1% or 2% rate of anything would have been collected and never printed. The longest exposure with posted results is 12 to 13 months, and male pattern hair loss runs on a multi-year time scale.

So what the video proposes is a mechanism and a set of hormone measurements, plus the inferences Tony draws from them. It does not say enclomiphene protects your hair, because no trial ever looked. It supplies androgen substrate like everything else here, and a genetically susceptible man who is already thinning has no free route to higher testosterone. It also does not tell you what to take or at what dose.

Keep going

For the wider comparison between running your own axis and replacing it, TRT vs Natural Testosterone: What Tony Huge’s Research Reveals is the next read. Companion write-ups for new videos go out to the tonyhuge.is email list first, and the full hormone and hair archive is on tonyhuge.is.

Popular Category